Information Management
EMA/451086/2021
September 2022

DADI eAF Project and PMS joint Q&A document

Digital Application Dataset Integration (DADI) Network Project and Product Management Service (PMS) Questions and Answers

Version 4

Disclaimer

This Question and Answer (Q&A) document is for information only and is based on insights available at the time of its release. The aim is to regularly update and rerelease this document. Nothing in this document should be taken as an explicit commitment on behalf of the EMA, the DADI project team or the PMS project team.

For convenience many technical terms are explained in the answers. In addition, there is a table of abbreviations at the back of this document.

For general inquiries, please contact the DADI project team via esubprogofficer@ema.europa.eu and the PMS project team via EMA Service Desk.

For questions or comments around the content of this Q&A document, please raise a ticket via the EMA Service Desk.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union

Contents

DIGITAL APPLICATION DATASET INTEGRATION (DADI) NETWORK PROJECT

DADI SCOPE

1. What will the DADI project deliver?

- The Digital Application Dataset Integration (DADI) Network Project will replace current PDF-based electronic applications forms (eAFs) with new web-forms in a new portal. During 2022 and 2023 the eAFs for variations and initial marketing authorisation will be replaced for human and veterinary medicinal products. Furthermore, the renewals eAF will also be replaced. Additional procedures will be considered.
- The web-forms will:
    - Support both centrally authorised product (CAP) applications at initial release of the forms and nationally authorised product (NAP) applications in subsequent releases for mutual recognition procedure (MRP), decentralised procedure (DCP), national procedures (NP) and, for veterinary, also subsequent recognition procedure (SRP). Additional forms for other procedure types will also be considered in future.
    - Standardise input for eAFs in order to effectively provide standard product master data for human and veterinary medicinal products.
    - Enable both the familiar human-readable (PDF) output and a new machine-readable output for digital processing based on the Fast Healthcare Interoperability Resources (FHIR) data exchange standard for medicinal products. The PDF rendition will be generated from the web User Interface and it will contain both the PDF document and an attached FHIR XML (ref. How will the project impact Competent Authorities?).
    - Use available product master data from Product Management Services (PMS) for human and the Union Product Database (UPD) for veterinary medicinal products to prepopulate form fields where relevant.
- The DADI project will *not* change:
    - The process to apply for or submit marketing authorisation applications.
    - The format of the current PDF output.
    - The content of the output form included in the application, changes to which are not governed by the project team.

Back to top

DADI BENEFITS

2. What are the main benefits that the web-forms will bring?

- The web-based forms will replace aging technology considered no longer fit for purpose, thus enabling progressive usability improvements for users over the current PDF forms through integration with PMS/UPD data. For example, upon release, the new forms will help applicants' form filling by using available PMS/UPD data to prepopulate form fields where relevant (product selection and structured product data where available).
- User-friendliness will improve over time as all the standardised Product and Substance Management Service databases become available, for example substances drop down lists will take much shorter time to load and will have less duplicate or confusing entries.
- The new forms are a means to enable more efficient application processing, reducing administrative burden. For example, the forms will support validation of applications by competent authorities, reducing errors and discrepancies.
- The forms will facilitate standardised, structured data being fed into databases making interoperability of systems and sharing of data between competent authorities much easier.

Back to top

DADI ROADMAP

3. Why is the DADI project running now?

- Work on replacing the electronic application forms with forms that would support efficiency and better interoperability was first undertaken as part of the Common European Single Submission Portal (CESSP) Phase 1 project started in 2016 and stopped in 2020.
- The need to replace the forms and align industry-facing applications has only increased since then, as the current Adobe PDF eAFs are aging, and risk no longer being fit for purpose.
- Momentum, relevant expertise and know-how built up during the CESSP Phase 1 project is there to be capitalised on by DADI. That is also the case with expertise on the technology chosen for the new web-forms which is the same as the IRIS Portal.
- Improvement of EMA's core processes is dependent on delivery of new forms facilitating standardised data entry for CAP applications. The data captured in forms is the entry point for data used throughout EMA's own core processes which are a key area for improvement over the coming months and years.
- The "Up-scaling the global univocal identification of medicines" (UNICOM) Horizon2020 project received funding to foster the implementation of ISO

IDMP and the usage of SPOR (Substances, Products, Organisations and Referentials) in the European Regulatory Network by 2023.
- In the context of the application form seven NCAs members of the European Medicines Regulatory Network are working together with EMA experts in the DADI project: AGES (Austria), BfArM (Germany), AEMPS (Spain), HPRA (Ireland), MEB-CBG (the Netherlands), NOMA (Norway) and SE MPA (Sweden).

Back to top

4. What are the next steps for DADI deliverables?

- The variation form for human medicinal products will be the first form to be released in 2022. This is a first release of the web-based variation form for human medicinal products that will be improved and expanded in subsequent releases in 2023. This progressive release model follows the Agile development model of the Agency.
- The scope of the first release of the variation form for human medicinal products will be limited to Centrally Authorised Products (CAPs). This version of the form cannot yet be used for applications containing Nationally Authorised Products (NAPs), including National Procedures, Mutual Recognition Procedure and Decentralised Procedure.
- A subsequent release of the form will support all types of EU variation procedures (CAPs and NAPs).
- The expected release order of forms after human variations will be confirmed at a later stage.
- The variation form for human medicinal products has been tested through closed User Acceptance Testing (UAT) with members of the DADI Subject Matter Expert Group, which were followed by testing of the PMS data (through a PMS UAT) that the forms will use.
- Finally, there will be integrated User Acceptance Testing focused on CAPs with a larger, but still limited, group of testers representing various stakeholders. The UAT sessions will take place from 19th September to 30th September 2022. A second UAT focused on both CAPs and NAPs will follow.
- The release of the variation form for human medicinal products supporting both CAPs and NAPs will be followed by a 6-month transition period during which both the PDF eAF and the web-based form can be used in parallel.
- At the end of the transition period, the use of the web-form which rely on structured PMS data will be required.
- Further details on User Acceptance Testing and subsequent development on other forms will be shared on a regular basis during the coming months.
- Communications around timeline are published on the DADI project page of the eSubmission website.

Back to top

5. Will there be User Acceptance Testing for the DADI deliverables?

- User Acceptance Testing (UAT) is the testing of the form by users to verify the requirements have been met.
- The UAT approach for the variation web-form for human has three steps:
  - Internal testing;
  - Data testing;
  - External testing.
- Internal testing is performed during the development sprints (according to the SAFe Agile methodology) and tests the functionality of the form with test data. Testing started in November 2021 and is performed by EMA staff and a selection of volunteers from the DADI SME Group. The SME Group comprises Subject Matter Experts from EMA, NCAs and industry and represent those respective stakeholder groups.
- Data testing will test the successful migration of the product data to PMS. The data testing is not in scope of the DADI project; however, it is a critical dependency.
- External testing will test the form's functionality and PMS data together. The aim is to facilitate testing by a wider group of stakeholders.
- A call for volunteers to participate in the first DADI UAT was launched between 7-15 July 2022 and the UAT will run from 19th September until the 30th September 2022. Note that the UAT aims to cover the most likely scenarios for different stakeholders. This means participation is limited. However, there will be other opportunities, starting from the second UAT for CAPs and NAPs applications and the transition period itself, to allow all users to familiarise themselves with the new tool.
- In addition to testing, the project team will demonstrate the new forms in one or more public webinars closer to their release dates.

Back to top

eAF WEB-FORMS

6. What will change technically in the forms?

- Applicants will fill out a web-based form instead of an interactive PDF form.
- The output, which the regulators will receive as part of the submission package, will include both the familiar human readable PDF document and an attached FHIR message which can be read and processed by IT systems.
- Submission of DADI variations forms will not differ from submission of the current eAFs.
- See Diagram 1 below for a visual description of technical changes:

Diagram 1 – Current situation vs future situation for eAFs



Back to top

7. Which will be the options available to create the eAF PDF in the new interface?

- Three options were considered by the DADI project team:
  - Using the web-based form to create applications and export to PDF with an attached FHIR message;
  - Creating the entire application FHIR message in an applicant's own system to submit to an Application Programming Interface (API) for validation and transformation into a PDF with attached FHIR message;
  - Importing a partial FHIR message into the web-based form to complete the application in the web User Interface.
- Of these three options, the first is what will be available upon initial release. This is the core feature of the web-based forms which enables a move away from the current PDF-based data input while also enabling the FHIR output attached to the PDF output to facilitate handling of applications.
- The second option is undergoing further analysis and design work to ensure validation of data provided through such a mechanism can be ensured. The third option is pending a technical feasibility analysis.

Back to top

8. Will the content requirements for the application form change?

- The web-based forms are the input forms to create the application, these will change to accommodate PMS/UPD data requirements.
- The output PDF rendition of the forms will look very similar to the current PDF eAF and will have the same information as the current forms.
- In addition, the FHIR XML backbone may contain additional metadata to facilitate regulatory activities.
- Details on all changes in data requested in the web-based form compared to the current eAF will be shared as part of the implementation and roll out.

Back to top

9. Is registration required to fill in an eAF?

- Every person involved in drafting an eAF needs an EMA account and can have different roles depending on access privileges. This enables saving forms online and co-authoring with other users. In case of co-authoring it is suggested to coordinate well with contributors, as there is the possibility of overwriting data if multiple people work on the same section simultaneously.
- Sign up will be possible before go-live to prepare access to the system.
- Each MAH has to make sure that consultants working on their behalf get an EMA role to see their products and are allowed to make changes. The IAM (Identity and Access Management) system will allow for two different types of consultant access: access to all products from that MAH or access to specific applications containing products.
- With regards to registration to user acceptance testing and production use, please consult the DADI webpage on the eSubmission website where information will be provided.

Back to top

10. Does the form need to be signed?

- It will be possible to sign the PDF rendition using own digital signature tools of the applicants. Details on the signature requirements will be available before go-live.
- The web-form contains the fields for the name of the signatories.

Back to top

11. Will the future forms still be called eAFs?

- The expectation is that the web-based forms will still be called electronic application forms (eAF).

- In DADI communications, EMA will frequently refer to web-based application forms to distinguish them from the current PDF format electronic applications forms. Technically both are electronic application forms.

Back to top

12. Will DADI deliver forms complying with the new Veterinary Medicines Regulation (Regulation (EU) 2019/6)?

- Veterinary forms are in scope for DADI. This means that when DADI web-based forms for veterinary medicinal products are released, they must comply with the Veterinary Medicines Regulation (Regulation (EU) 2019/6).
- Due to the regulatory risks and the development risks of the form, the Steering Committee of DADI decided to decouple the development of the veterinary variations web-based form from the regulatory deadline of 28 January 2022. Instead, the current PDF format electronic variation application form has been updated to support regulatory requirements for the 28 January deadline.
- The main benefit of this approach is that there will be a reduced risk of new technology disrupting the transition to the new regulatory requirements. In addition, it means that a transition period can be facilitated, which will benefit from lessons learned from rolling out the human variations form.
- Development work on the veterinary web-form will start at a yet to be determined time.
- In the meantime, veterinary representatives participating in the DADI SME Group have been invited to stay on as observers to ensure a smooth uptake of veterinary requirements once development starts.

Back to top

13. What is the connection between the web-based forms and UPD for veterinary medicinal product data?

- The UPD refers to the requirement for a new Union Product Database for all authorised veterinary medicinal products as per the veterinary medicinal products regulation, EU Regulation 2019/6. The UPD is accessible to the general public and will be a searchable database.
- UPD uses the same data repository for product master data as PMS, and it is commonly referred to as UPD to distinguish it from product master data for human medicinal products.
- The new web-forms will standardise input for eAFs in order to effectively provide standard UPD data.
- The web-forms will also use available UPD data to prepopulate form fields where relevant.
- FHIR was selected as the application programming interface for the common PMS and UPD data repository and the web-based forms are an example of

FHIR being used to read data from the application programming interface and display it in the web forms.

Back to top

14. Who will maintain the new web-based forms?

- The system facilitating the forms will be technically maintained and supported by EMA.
- The EMA Service Desk will be available to address issues and there will continue to be opportunities for applicants and other stakeholders to propose features.
- Until further notice the existing eAF Maintenance Group, which plays a key role in maintaining the current forms as well as providing expertise on the new, web-based forms, will continue.
- As part of DADI, the governance will be reviewed, transparently, with the expectation that a subject matter expert body, such as the current eAF Maintenance Group, will continue to exist with EU Regulatory Network and industry representation.

Back to top

15. Will the use of web-forms be mandatory for CAPs and NAPs at the same time?

- At this point in time there is no plan to differentiate between CAPs and NAPs. The use of the variation web-forms will become mandatory for both CAPs and NAPs at the end of the transition period.

Back to top

16. Will all products (CAPs and NAPs) be searchable within the eAF from the first DADI release?

- No, at the time of the first release of the variations web-based eAF only CAPs will be available. All products (CAPs and NAPs) will be searchable according to access management rules from the release of the form supporting both CAPs and NAPs applications.

Back to top

17. Are the forms still owned by the NtA group?

- Yes, for human medicinal products the European Commission Notice to Applicants (NtA) expert group will remain responsible for the content requirements of the application forms.
- The web-based forms will meet these content requirements. They will however also ask additional information to support efficient handling of applications and SPOR data management services.

Back to top

18. How will stakeholders be notified of future changes to the forms?

- The web-based forms will support both Centrally and Nationally Authorised Products applications – requiring some coordination around updates and changes.
- The change control and maintenance processes are part of DADI's deliverables. However, they have not been agreed yet at this time.

Back to top

STAKEHOLDERS

19. How is DADI taking stakeholder perspectives into account?

- DADI is a Network project as it addresses both Centrally Authorised Product Applications and Nationally Authorised Product Applications.
- The DADI project has established a Subject Matter Expert Group (formerly: Requirements Group) which represents Subject Matter Experts from EMA, NCAs and Industry. Participation to the group is limited.
- The SME Group meets on a weekly basis and provides expert insight into the use of forms, as well as provides input for EMA requirements for CAPs and NCA requirements for NAPs.
- The SME Group is also involved in testing of the forms.
- The project planning and implementation are following Safe Agile principles. Product ownership of the web-forms is shared between EMA and NCA representation, which means requirements gathering and design is done collaboratively between EMA and the Network.
- Product ownership for NCAs is an in-kind contribution of the UNICOM consortium.

Back to top

20. How is UNICOM contributing to DADI?

- UNICOM is a European Commission (EC) Horizon2020 funded consortium separate from the European Medicinal Network's IT governance structure.
- Two of its objectives relate to ensuring the availability of Pan-European IDMP Compliant forms (Work Package 3) and IDMP implementation at National Agencies (Work Package 4). UNICOM has an inbound dependency on the DADI project for Work Package 3.
- UNICOM provides in-kind contributions to DADI project work and the web-forms for among others: a product owner, communication and training to

NCAs and applicants, supporting NCAs to automatically import form data, liaison with the Notice to Applicants Expert Group, contributing to UAT and IT development for FHIR messages and PDF representations for NCAs.
- EMA has no contractual obligations towards the UNICOM Consortium and the European Commission.

Back to top

21. How will the project impact Competent Authorities?

- The web-based application forms will be common for both NAPs as well as CAPs which are processed by NCAs and EMA respectively.
- The forms impacted are used in NCA relevant authorisation procedures:
  - mutual recognition procedure (MRP);
  - decentralised procedure (DCP);
  - national procedure (NP);
  - subsequent recognition procedure (SRP) for veterinary.
- The web-based forms create opportunities to automate manual processes related to processing forms and facilitate the collection of standardised data.
- Competent authorities that are not currently using the PDF forms' Extensible Markup Language (XML) functionalities will notice little change – the PDF output of the web-based form may look a little different.
- Competent authorities currently using the PDF forms' XML functionalities will need to adjust their systems to accommodate the new FHIR compliant XML.

Back to top

22. How will the project impact industry stakeholders?

- The current PDF format variation eAF will be replaced by a web-based user input form for CAPs and NAPs applications. At initial release, the web-based form will support CAP applications only. A subsequent release of the form will support all types of EU variation procedures (CAPs and NAPs).
- Any new web-based application form will be prepopulated with available PMS/UPD data. Industry will have visibility of data available on the regulator's side.
- The forms will support the collection and use of standardised PMS/UPD product master data.
- DADI is currently developing the human variation form. Once this moves to external testing and, later, release and implementation, a more detailed breakdown of possible impacts for Industry will be made available.

Back to top

TRAINING

23. Will there be training?

- As part of the roll-out of the new forms, a learning offering will be made available approaching their release.
- EMA and NCAs are cooperating to provide support, guidance and training for applicants as the roll-out of the first form (variations) approaches.
- In addition, applicants and stakeholders can expect several webinars to support roll-out and answer questions.
- User guides are being developed to fully support the web-based forms. The portal guide to registration has been published on the eSubmission website, while the navigation guide will be made available soon.
- There will be help online and on-screen tooltips within the system.

Back to top

DADI & IRIS

24. What is the difference between DADI and IRIS?

- IRIS is EMA's online platform to support product-related scientific and regulatory procedures with EMA.
- The future portal for eAFs will host application forms for all EU procedures (CP, MRP, DCP, NP, SRP). After filling in the web-based form, the applicant will generate a PDF which is submitted through existing eSubmission channels as part of eCTD package.
- IRIS and the future portal for eAFs serve different purposes and will be governed differently. However, the intention is to facilitate and develop ease of use across the two portals wherever feasible.
- For instance, the aim is to have the new portal benefit from the same access control model with user accounts and affiliations managed via the separate EMA Account Management System. This determination is still to be definitively made.
- IRIS is implemented using several technologies that will be also used to deliver the DADI project, i.e. Microsoft PowerApps. Experience gained by EMA in building IRIS is helping to implement DADI.

Back to top

ISO-IDMP & DATA

25. What is ISO IDMP?

- The International Organisation for Standardisation (ISO) standard for identification of medicinal products (IDMP).

- ISO IDMP specifies the use of standardised definitions for the identification and description of medicinal products for human use.
- Their purpose is to facilitate the reliable exchange of medicinal product information in a robust and consistent manner.
- They help to ensure wide interoperability across global regulatory and healthcare communities, which is critical in ensuring accurate analysis and unambiguous communication across jurisdictions.
- Commission Implementing Regulation (EU) No 520/2012 (articles 25 and 26) obliges EU Member States, Marketing Authorisation Holders (MAHs) and EMA to make use of the ISO IDMP standards. This will impact on many areas of the pharmaceutical regulatory environment, both in the EU and other regions.
- For more information, see this Introduction to ISO IDMP and SPOR.

Back to top

26. Will the data requested in forms for human medicinal products be ISO IDMP-compliant?

- The intention is to facilitate exchange of standardised master data, therefore, the forms will use PMS data which comply with ISO IDMP standards for human medicinal products.
- The scope of ISO IDMP and SPOR is different: ISO IDMP covers the entire medicinal product lifecycle, including development, while PMS in SPOR covers only the Authorised Medicinal product part of IDMP.
- ISO IDMP covers human medicinal products only.
- See this presentation for further details on the relation between SPOR, ISO IDMP and FHIR.

Back to top

27. Will it be possible to download/export products data from the web User Interface?

- The users will be able to see the relevant product data via the web UI and download the forms which contain such data. However, there will be no dedicated capability neither to export only product data nor to perform bulk exports in the web UI.

Back to top

FHIR

28. What is FHIR?

- Fast Healthcare Interoperability Resources (FHIR) is a standard for exchanging healthcare information electronically.
- The DADI project team will create a FHIR specification as backbone for each of the new web-based forms.

- FHIR is the machine-readable language chosen to support the easy exchange of data between DADI's forms, systems and product databases such as PMS and UPD.
- FHIR aims to simplify implementation without sacrificing information integrity. It leverages existing logical and theoretical models to provide a consistent, easy to implement, and rigorous mechanism for exchanging data between healthcare applications.
- The basic building block in FHIR is a Resource. All exchangeable content is defined as a resource. Resources all share the following set of characteristics:
    - A common way to define and represent them, building them from data types that define common reusable patterns of elements;
    - A common set of metadata;
    - A human readable part.

Back to top

29. How will the eAF FHIR message relate to the PMS/UPD messages?

- The eAF FHIR message comprises two major parts: (1) the procedure part, known as the task resource, and (2) the medicinal products part. The procedure part is eAF specific, while the medicinal products will be represented through FHIR resources which match those of PMS and UPD.
- A resource is the basic building block in the FHIR standard. All exchangeable content is defined as a resource. Resources all share the following set of characteristics:
    - A common way to define and represent them, building them from data types that define common reusable patterns of elements;
    - A common set of metadata;
    - A human readable part.
- There may be some additional resources and elements in the product part for the eAF that are needed only for a given regulatory procedure i.e. not to be reused. These will not be entered into PMS or UPD.

Back to top

30. Will the mapping of the FHIR resources used by DADI with IDMP be published?

- The medicinal product resources used in common by PMS and DADI have the same name, so users can look for them in PMS EU IG Chapter 2. The FHIR resources have the mapping to IDMP present in FHIR already (e.g. http://hl7.org/fhir/2021May/medicinalproductdefinition-mappings.html).

Back to top

31. Will the FHIR message that is embedded in the DADI PDF export be used to update PMS from the initial go-live of DADI?

- This will not happen at the go-live of DADI, and submissions to Art. 57 are still needed. In the future, the idea is to use the data provided in the DADI variation form in order to update the data in PMS.

Back to top

32. Is an HTML FHIR viewer publicly available?

- Proprietary tools to transform FHIR XMLs to HTML are publicly available.

Back to top

SPOR

33. What is SPOR?

- SPOR is an acronym used to refer to the four domains of pharmaceutical master data: Substance, product, organisation and referential (SPOR) master data
- The EMA and the European medicines regulatory network agreed to implement the ISO IDMP standards for the identification of medicinal products in a phased programme, based on these four domains of master data in pharmaceutical regulatory processes.
- More information related to SPOR can be found in Substance, product, organisation and referential (SPOR) master data | European Medicines Agency (europa.eu)

Back to top

Product Management Service (PMS)

PMS SCOPE

34. What is PMS?

- PMS is the Product Management Service for product master data for human medicinal products. It is one of the four data management services for human and veterinary medicinal products known as SPOR (substance, products, organisations and referentials). For Veterinary medicinal products, the Union Product Database (UPD) is the service through which product master data is provided.

Back to top

35. What will PMS deliver?

- The Product Management Services (PMS) makes available comprehensive and consolidated data on centrally authorised products (CAPs) and non-centrally authorised products (non-CAPs) from different sources across the European Medicines Regulatory Network, that is structured, standardised, authorised to be used by regulators and industry in regulatory and non-regulatory procedures, as well for the general benefit of European citizens.
- The Product Management Services (PMS) enables the implementation of globally recognised ISO standards for the identification of medicinal products (IDMP).
- The PMS implementation process is iterative, in steps. The first iteration of the PMS will cover a subset of the authorised **medicinal product** part of the ISO IDMP standards**.** As part of this iteration, the new ISO IDMP compatible data submission format (HL7 FHIR) replaces the current data submission format, the eXtended EudraVigilance Product Report Message (XEVPRM).
- Future PMS iterations will implement other product data elements of the authorised medicinal product and the investigational medicinal product part of the ISO IDMP standards.

PMS BENEFITS

36. What are the main benefits of PMS?

- PMS is an implementation of globally recognised ISO standards for the identification of medicinal products (IDMP). Through this PMS allows everyone to align to one standard set of rules for product data. That enables the exchange of interoperable data, greatly facilitating processes of many different data users including administrative processes of regulators.

- PMS specifically creates process efficiencies by delivering comprehensive and consolidated medicinal product data (CAP and Non-CAPs) from different sources which can be re-used in electronic applications and throughout regulatory processes. Assessment as part of the regulatory procedure can come to use commons, standard data, removing much of ambiguity and interpretation of data during the assessment.

Back to top

PMS TIMELINE

37. When will PMS be delivered?

- The PMS product will be delivered in multiple releases. Each release will either add or improve features. PMS will release both standalone as well as part of other IT products, such as electronic applications.
- The migration of CAP medicinal product data from the EMA database (SIAMED II) has been delivered in May 2021. PMS makes available Centrally Authorised Product (CAP) data in ISO IDMP compliant format, as per dossier business rules and validated by EMA.
- CAP medicinal product data provided by PMS is already used internally by EMA to support the manufacturer audit process. The variations eAF web form release 1 will also use CAP medicinal product provided by PMS.
- The migration of medicinal product data from XEVMPD is ongoing and in Q1 2023, PMS will also contain NAP products.
- Future releases of PMS will:
    - Allow Industry to access, see and export the data in PMS;
    - Enable pharmaceutical companies to correct and complete PMS product data;
    - Enable data approved within a regulatory application to be stored in the PMS;
    - Ensure adequate data quality in the PMS so that it can be confidently reused across procedures;
    - Replace Art. 57 submission process, data format and data content.

Back to top

38. When will the User Interface be delivered?

- At the moment, there is no User Interface to check the data in PMS, and the only way to see product data is through the DADI platform, where specific product data coming from PMS is shown.
- EMA is working on developing and releasing a User Interface.
- EMA will communicate the date when the User Interface will be made available for use in due course and via the official EMA Agile channels.

Back to top

PMS DATA

39. What will happen to xEVMPD?

- xEVMPD is the current database used by Industry to submit and maintain product data (both CAPs and non-CAPs). This data is used by EMA and NCAs for several processes.
- Continuity of these processes is important and therefore until a full migration to PMS is feasible, xEVMPD will be maintained.
- EMA is working to guarantee that duplicate submissions to PMS and xEVMPD by Industry will not be necessary and in due course the new ISO IDMP compatible data submission format (HL7 FHIR) will replace the current data submission format, the eXtended EudraVigilance Product Report Message (XEVPRM).
- Until further notice the current process for submission of product data to xEVMPD should be used.

Back to top

40. Where does the data in PMS come from?

- For the first release of the DADI eAF web forms which support CAP products only, the data in PMS will come from SIAMED II. SIAMED II is the internal EMA database where CAP product data is stored and maintained. EMA migrated product data from SIAMED to PMS. All the information related to this migration exercise can be found on Annex I to Chapter 7 available at Products Management Services (PMS) - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe (europa.eu)
- For release 2 of the DADI eAF web forms, which will support not only CAPs but also non-CAP products, xEVMPD data will also be migrated to PMS. XEVMPD data is provided and maintained by MAHs for both CAPs and Non-CAPs. Chapter 7 of the EU IG will be updated to provide all the information on the business rules used by EMA to migrate the data from both sources, I.e.: SIAMED II and xEVMPD.
- For the time being, any update to product data done in SIAMED II or xEVMPD, will also be reflected in PMS.

Back to top

41. How will I see data in PMS?

- PMS team will provide a User Interface where users will be able to see the data available in PMS.

- On the PMS roadmap is also the intent to create API connection for users that prefer to connect their internal systems to PMS.
- For the time being, as the User Interface and the API connection are not available, PMS data can only be seen through the DADI eAF web forms.

Back to top

42. How do I correct or complete my data in PMS?

- If data found in PMS originating from xEVMPD is wrong or not up to date, users can submit updates through xEVMPD to amend data in PMS. In case the source of information is SIAMED, a process will be established and shared with the stakeholders.
- EMA is working on releasing a User Interface and API connections to allow users to correct and/or complete missing data in PMS. The process and timelines for these corrections/enrichments is still under discussion. More information will be shared in due time.

Back to top

PMS & DADI

43. What is the difference between DADI and PMS?

- PMS is the Product Management Service for product master data for authorised human medicinal products. It is one of the four data management services for human and veterinary medicinal products known as SPOR (substance, products, organisations and referentials). For Veterinary medicinal products, UPD is the service through which product master data is provided.
- DADI refers to the initiate to develop an IT product that replaces the PDF-format eAFs and the new web-forms.
- PMS will be the means to:
    - Standardise input for eAFs to effectively provide standard product master data for human and veterinary medicinal products.
    - Use available product master data to prepopulate form fields where relevant.

Back to top

44. How is PMS go-live impacted by DADI eAF web-form releases?

- PMS go-live, i.e. its first public release, is linked to the DADI eAF web-form release calendar, as variation forms for human medicinal products will be the first publicly available system that will consume data from PMS.

- This is expected to impact the original PMS release plan described in chapter 3 of the EU IG. A review of this release plan is underway.

Back to top

PMS IMPLEMENTATION GUIDANCE

45. What is the PMS Implementation Guide and which is the latest available version?

- The PMS EU Implementation Guide for the submission of data on medicinal products defines the implementation requirements of the ISO IDMP standards and will be the basis for submission and exchange of medicinal product data in the EU.
- The current version of PMS EU Implementation Guide is version 2.1.1, released in July 2022.
- The PMS EU Implementation Guide is updated on an as needed basis when enough material changes merit updating the document.
- Future releases of the EU Implementation Guide will be announced in advance and follow appropriate stakeholder consultation procedures.

Back to top

STAKEHOLDERS

46. How is the European Medicines regulatory Network involved in PMS?

- PMS is a Network initiative that addresses both Centrally Authorised Product and Nationally Authorised Products.
- The PMS product team is in the process of establishing a Subject Matter Expert Group with Subject Matter Experts from EMA, NCAs and Industry in order to bring insight and expertise from all users of PMS to the table.
- The SME Group will meet on a weekly basis and provides expert to the PMS product owners.
- The SME Group is also involved in testing of PMS before releases.
- Product ownership of PMS is intended to be shared between EMA and NCA representation, which means requirements gathering and design is done collaboratively between EMA and the Network.

Back to top

47. How is industry currently consulted in PMS development and implementation?

- The EMA works closely with industry stakeholders and its partners in the European medicines regulatory network to guide strategic priorities and

ensure that the EMA's IT development portfolio creates the optimal value for all stakeholders.

- At the strategic and portfolio level Industry is engaged through to annual Strategic Portfolio Review ceremonies. Additionally, EMA Executive Board has bilateral meetings with Industry on an annual basis.
- At the execution level, the EMA is in the process of establishing a Subject Matter Expert (SME) Group for PMS, including industry SMEs, which provides expert insight and advice to the PMS Product Owners, and are closely involved with the solution design. from EMA, NCAs and Industry.
- The PMS SMEs and (network) Product Owner will succeed governance as originally established for SPOR.

Back to top

HELP

48. My question is not answered here, what do I do?

- The DADI and PMS projects are still ongoing therefore not all questions have definitive answers. As topics are clarified the project team will share details and supporting documentation, including updates to this Q&A document.
- Applicants wondering about specific features and interests can consider contacting an industry association representative on the SME group or contacting EMA directly.
- For general inquiries, please contact the DADI project team via esubprogofficer@ema.europa.eu. For questions or comments around the content of this Q&A document, please raise a ticket (by selecting "Ask a question" and including in the subject "DADI Q&A") via the EMA Service Desk.
- If you have a technical question about the current eSubmissions systems or the DADI project, please raise a ticket (by selecting "Ask a question" and including in the subject "DADI") via the EMA Service Desk.
- If you have any question related to PMS, please raise it via the EMA Service Desk.

Back to top

Table of abbreviations

AEMPS	Agencia Española de Medicamentos y Productos Sanitarios	AGES	Austrian Agency for Health and Food Safety

AMP	Authorised Medicinal Product
API	Application Programming Interface
BfArM	Bundesinstitut für Arzneimittel und Medizinprodukte
CAP	Centrally Authorised Product
CESSP	Common European Single Submission Portal
CP	Centralised Procedure
DADI	Digital Application Dataset Integration
DB	Database
DCP	Decentralised Procedure
eAF	Electronic Application Form
eCTD	electronic Common Technical Document
EV Code	Eudra Vigilance Code
EEA	European Economic Areas
EC	European Commission
EU	European Union
EMA	European Medicines Agency
EMRN	European Medicines Regulatory Network
xEVMPD	Extended EudraVigilance medicinal product dictionary
FHIR	Fast Healthcare Interoperability Resources
H	Human
HL7	Health Level 7
HPRA	Health Products Regulatory Authority
IAM	Identity and Access Management
IDMP	Identification of Medicinal Products
IG	Implementation Guide
IT	Information Technology

ISO	International Organization for Standardization
MEB	Medicines Evaluation Board
MAA	Marketing Authorisation Application
MAH	Marketing Authorisation Holder
MRP	Mutual Recognition Procedure
NAP	Nationally Authorised Product (generally used in this document to describe products authorised via MRP/DCP/NP)
NCA	National Competent Authority
NOMA	Norwegian Medicines Agency
NP	National Procedure
NtA	Notice to Applicants
PMS	Product Management Services
PSMFL	Pharmacovigilance System Master File
QPPV	Qualified Person for PharmacoVigilance
RIMS	Regulatory Information Management System
SME Group	Subject Matter Experts Group
SE MPA	Swedish Medical Products Agency
SPOR	Management Services for Substances, Products, Organisations and Referentials
SRP	Subsequent Recognition Procedure
Q&A	Questions & Answers
UAT	User Acceptance Testing
UI	User Interface
UNICOM	Up-scaling the global univocal identification of medicines project
UPD	Union Product Database
VA	Variation Application
Vet	Veterinary

VMP	Veterinary Medicinal Products
VNees	Veterinary non-eCTD electronic submission.

xEVMPD	Extended EudraVigilance Medicinal Product Dictionary
XML	Extensible Markup Language